Personalized treatment for advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This study tests whether giving treatment based on the specific markers of your tumor can better control advanced stomach cancer. The goal is to match the right therapy to each person's cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have advanced stomach cancer or cancer at the junction of the stomach and esophagus.
- You have not had systemic treatment for advanced disease, but if you relapsed more than 6 months after finishing prior therapy, you may be eligible.
- You have at least one measurable tumor lesion.
- You have a tumor tissue sample available for biomarker testing (HER2, CLDN18.2, and PD-L1).
- You are physically active (ECOG 0-1) and expected to live at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This trial tests a combination of an immunotherapy drug (sintilimab) and two chemotherapy drugs (nab-paclitaxel and tegafur) as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps people live longer and controls the cancer better.
This trial tests a combination of two drugs—nab-paclitaxel (a chemotherapy drug) and cadonilimab (an immunotherapy drug)—for people with advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this combination can help shrink or control the cancer when other treatments haven't been tried yet.
This trial tests whether combining different drugs before and after surgery can help people with locally advanced stomach cancer that can't be removed right away. The goal is to see which combination works best to shrink the tumor and improve outcomes.
This study tests a treatment approach for stomach cancer that hasn't spread to other organs. It's for people who have not had any prior cancer treatments and are in relatively good health.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.